Epax reports interim results from the phase III study on AKR 963

Epax, a company that Aker BioMarine owns 50/50 together with Lindsay Goldberg,
today reported that the company's pharmaceutical product, AKR 963, met the
primary endpoints in the ongoing phase III clinical trial. The press release
from Epax is attached.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1566009]